A narrower follow-up, since the general answer is now clear:
Why a shortage listing created a legal pathway at all, since a shortage is a supply fact rather than a permission?
InsuranceTom said:The shortage clause is the answer to the second question and it is a subtraction rather than an addition.
This is where I part company with the consensus forming above. This treats a plausible mechanism as a demonstrated one. Plausible is where you start looking, not where you stop.
InsuranceTom said:The shortage clause is the answer to the second question and it is a subtraction rather than an addition.
Correct as far as it goes. The part it does not cover is what to do when the honest answer is "not enough data", which is more often than anyone likes.
Certified reference materials, analytical reagents, and research-grade standards for peptide verification. Trusted by laboratories worldwide.
Shop Reference StandardsInsuranceTom said:The shortage clause is the answer to the second question and it is a subtraction rather than an addition.
This answered a question I did not know how to ask. Printing the relevant bit and taking it with me.
Clinical perspective, offered as context rather than as advice. The mechanism and the magnitude are separate questions. Agreeing that something happens says nothing about whether it happens enough to act on.